Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropivacaine dilution for blinding nerve blocks
NCT06668116Completed
- Sponsor
- University Hospital Balgrist
- Start
- Dec 2024
- Primary completion
- Oct 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in pain (2 arms), sponsored by University Hospital Balgrist. Primary endpoints: Heat pain sensitivity at 60 months, Self-report of sensory block at 60 months and 1 more. Started Dec 2024; status: completed.
02
Drugs
ropivacaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06668116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06668116.